Skip to main content
Fig. 2 | Trials

Fig. 2

From: Follow up after sample size re-estimation in a breast cancer randomized trial for disease-free survival

Fig. 2

Hazard rate for recurrence or death for the sample size re-estimation (SSRE) cohort at the time of re-estimation (a) and through the final follow up (b). a At SSRE, n = 278, average follow up 1.2 years. b At final follow up, average follow up 4.2 years. Black line indicates the scheduled/luteal-phase-surgery group; gray line is for the immediate/follicular-phase-surgery group. Dashed lines are pointwise 95% confidence intervals

Back to article page

Trials

ISSN: 1745-6215